| OA04.04 | Design and testing of a cabotegravir reservoir implant for HIV prevention | Oral Abstract Session | Delivery technologies: novel approaches, formulation and multi-purpose |
| OA04.05LB | Trial design, enrollment status, demographics, and pharmacokinetics (PK) data from a blinded interim analysis from a phase 2a trial of Islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP) | Oral Abstract Session | Clinical trial results |
| OA05.01 | Role of HLA-E antigen presentation on NK control of HIV infection | Oral Abstract Session | Innate and trained immunity |
| OA05.02 | Acute SIV Induces BHLH gene variants prior to adaptive natural killer cell formation | Oral Abstract Session | Innate and trained immunity |
| OA05.03 | Compartment specific changes of Innate Lymphoid Cells within the intestinal mucosa of HIV-1 infected individuals | Oral Abstract Session | Microbiome & STI: impact on prevention |
| OA05.04 | Disruption of immune cell homeostasis within rectal mucosal tissue of HIV+ young men who have sex with men | Oral Abstract Session | Mucosal immunity |
| OA06.01 | Pharmacokinetics, safety, and vaginal bleeding associated with continuous versus cyclic 90-day use of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy | Oral Abstract Session | Contraception, pregnancy and HIV prevention (incl. PMTCT) |
| OA06.02 | Randomized, placebo-controlled trial of safety, pharmacokinetics, and pharmacodynamics of 90-day intravaginal rings (IVRs) releasing tenofovir (TFV) with and without levonorgestrel (LNG) among women in Western Kenya | Oral Abstract Session | Delivery technologies: novel approaches, formulation and multi-purpose |
| OA06.03 | Randomized, Placebo Controlled Phase I Trial of Safety, Pharmacokinetics, Pharmacodynamics and Acceptability of a Multipurpose Prevention Vaginal Ring Containing Tenofovir and Levonorgestrel | Oral Abstract Session | Clinical trial results |
| OA06.04 | Heterosexual couples' preferences for dual-purpose prevention products for HIV and pregnancy prevention: the CUPID Study (MTN-045) in Uganda and Zimbabwe | Oral Abstract Session | Delivery technologies: novel approaches, formulation and multi-purpose |